AC
MLTX icon

AXQ Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

AXQ Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$359K Buy
+19,241
New +$319K 0.05% 534

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AXQ Capital's MLTX Position: Q1 2026 in Review

AXQ Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 19,241 shares worth $359K. The stake represents 0.05% of the portfolio and ranks #534 among its holdings.

147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • AXQ Capital held 19,241 shares of MoonLake Immunotherapeutics worth $359K as of Q1 2026.
  • MoonLake Immunotherapeutics was a new AXQ Capital position in Q1 2026.
  • MoonLake Immunotherapeutics made up 0.05% of AXQ Capital's portfolio in Q1 2026, its #534 holding.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.